NYSE:EWMedical Equipment
Is Edwards’ RESILIA Trial Success And New CFO Appointment Altering The Investment Case For EW?
Earlier this month, Edwards Lifesciences reported 10-year COMMENCE aortic trial results showing durable performance of its RESILIA tissue valves, and named Theodora (“Doretta”) Mistras, formerly Viatris CFO and a long-time healthcare investment banker, as its new chief financial officer, effective at the end of May.
Together, the reinforced clinical evidence for RESILIA technology and the appointment of a financially seasoned healthcare leader could be important for how investors view...